PACB Pacific Biosciences of California Inc.

PacBio Partners with The European Reference Genome Atlas Initiative

PacBio Partners with The European Reference Genome Atlas Initiative

Partnership to improve biodiversity research, accelerate conservation with actionable and accurate genomic data

MENLO PARK, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: PACB)(“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, highly accurate sequencing platforms, today announced a partnership with The (ERGA) consortium to support its efforts in understanding and protecting biodiversity by generating high-quality reference genomes for European plant and animal species.

Biodiversity is under threat worldwide with a high number of European species at risk of extinction1. Genomics is a powerful tool to help understand biology and how ecosystems function. PacBio’s HiFi Sequencing technology allows scientists to take the first important step by reliably generating high-quality genetic maps of each plant and animal species. Studies have shown that reference-quality genomes provide the most complete insight into the genetic basis that forms each species2.

“Together, PacBio and ERGA aim to put Europe’s biodiversity on the path to recovery by 2030,” said Neil Ward, Vice President and General Manager of EMEA at PacBio. “Each plant and animal species has a unique genome and they range in complexity. Since HiFi Sequencing reads are both large and accurate, scientists can easily assemble, phase, and analyze genomes with confidence.”

ERGA seeks to increase coordination across all countries of the European continent, in tandem with international partners, to generate reference-quality, complete and error-free genome assemblies for at least 200,000 plant and animal species - across Europe.

“With accurate reference genomes, scientists can gain the most complete insight into a species’ genetic basis to understand its evolutionary history and also predict its future adaptation potential,” said Camila Mazzoni, Chair, ERGA, Research Group Leader at Leibniz Institute for Zoo and Wildlife Research. “We’re excited to welcome PacBio to the ERGA initiative and look forward to our coordinated effort to generate complete reference genomes for all European biodiversity, which will accelerate conservation initiatives and advance biodiversity genomics innovation.”

This partnership expands PacBio’s continued support for worldwide and regional consortiums, including the Darwin Tree of Life and Aquatic Symbiosis Genomics initiatives with the Wellcome Sanger Institute, the Vertebrate Genomes Project, the Earth BioGenome Project and the California Conservation Genomics Project. These initiatives are dedicated to preserving, monitoring and cataloging biodiversity with actionable and accurate genomic data.

To learn more, please visit the .

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ: PACB) mission is to enable the promise of genomics to better human health and to create the world’s most advanced sequencing technologies. Today, the company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology. For more information, please visit  and follow .

About the European Reference Genome Atlas (ERGA) Initiative

Under the umbrella of the (EBP), ERGA is part of a large network of global biodiversity genomics consortiums. ERGA is a people-based initiative that is entitled to be fully inclusive, diverse, and equal across all European countries with the aim to put Europe’s biodiversity on the path to recovery by 2030 for the benefit of people, climate, and the planet. The program is currently developing a framework for the Pan-European interconnection of expertise in the field of biodiversity genomics, building upon existing infrastructure and applying for support to the Horizon Europe Programme. The implementation of a European hub to EBP is responding to a call of the European Commission, to tackle challenges resulting from climate change, help to achieve the UN’s Sustainable Development Goals and boost Europe’s competitiveness and growth.

PacBio products are provided for research use only. Not for use in diagnostic procedures.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements relating to PacBio’s partnership with ERGA and related support to generate reference genomes, including the number and types of genomes; benefits of using HiFi Sequencing technology, including in connection with the assembly, phasing and analysis of genomes; biodiversity recovery efforts; the acceleration of conservation initiatives and biodiversity genomics innovation. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the following cautionary statements. All forward-looking statements speak only as of the date of this press release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements. Readers are strongly encouraged to read the full cautionary statements contained in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Forms 8-K, 10-K, and 10-Q. The Company disclaims any obligation to update or revise any forward-looking statements.

Contacts

Investors:

Todd Friedman

+1 (650) 521-8450

 

Media:

Jen Carroll

+1 (858) 449-8082

 

_____________________

1 Borrell, B. One-fifth of invertebrate species at risk of extinction. Nature (2012). Published 2012 Sept 03. /10.1038/nature.2012.11341

2 Brandies P, Peel E, Hogg CJ, Belov K. The Value of Reference Genomes in the Conservation of Threatened Species. Genes (Basel). 2019;10(11):846. Published 2019 Oct 25. doi:10.3390/genes10110846



EN
27/09/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacific Biosciences of California Inc.

 PRESS RELEASE

PacBio Announces Third Quarter 2025 Financial Results

PacBio Announces Third Quarter 2025 Financial Results MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results:  Q3 2025Q3 2024Revenue$38.4 million$40.0 millionInstrument revenue$11.3 million$16.8 millionConsumable revenue$21.3 million$18.5 millionService and other revenue$5.8 million$4.7 millionRevio™ systems1322Vega™ systems32—Annualized Revio pull-through per system~$236,000~$255,000Cash, cash equivalents, and investments$298.7 million$471.1 million Gross margin, operat...

 PRESS RELEASE

HiFi Solves Consortium Publishes First Major Study Demonstrating the C...

HiFi Solves Consortium Publishes First Major Study Demonstrating the Clinical Research Power of PacBio HiFi Genomes New multi-center study identifies 100% of clinically relevant variants in the study, including those not detected by short-read sequencing technologies, positioning HiFi as the bridge between research and clinical-grade genomics MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced the publication of a new preprint from the HiFi Solves EMEA Consortium, “.” The study shows...

 PRESS RELEASE

PacBio Supports Berry Genomics in Achieving First Regulatory Approval ...

PacBio Supports Berry Genomics in Achieving First Regulatory Approval for Clinical Long-Read Sequencing in China NMPA approval on the Sequel II CNDx system enables clinicians in China to harness PacBio HiFi sequencing for challenging conditions, with initial offering for thalassemia MENLO PARK, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced that, through its long-standing partnership with Berry Genomics, the Sequel II CNDx system has received Class III Medical Device Registration approval f...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

6550-6569 S&P 500 Support Holding For Now After 5.5-months, the S&P 500 (SPX) has now failed to break and stay below the its 20-day MA. However, 6569 has been our level that needs to break in order for us to have confidence that a pullback has begun; SPX made a low of 6551 on Friday (less than 20 points or 0.3% from our 6569 level), meaning it was not a decisive breakdown (in time or price). As a result, our near-term bullish outlook since our 4/22/25 Compass remains intact, and it will stay t...

 PRESS RELEASE

PacBio to Report Third Quarter 2025 Financial Results on November 5, 2...

PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025 MENLO PARK, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2025 financial results on Wednesday, November 5, 2025, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio’s website at . Date: Wednesday, November 5, 2025, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the ca...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch